This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Proglumetacin is a non-steroidal anti-inflammatory medication used to manage pain associated with various inflammatory conditions including rheumatoid arthritis and osteoarthritis.
- Generic Name
- Proglumetacin
- DrugBank Accession Number
- DB13527
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Proglumetacin (DB13527)
- Weight
- Average: 844.45
Monoisotopic: 843.3973915 - Chemical Formula
- C46H58ClN5O8
- Synonyms
- Proglumetacin
- Proglumetacina
- Proglumétacine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Osteoarthritis (oa) •••••••••••• •••••••• •••••• Symptomatic treatment of Pain •••••••••••• •••••••• •••••• Symptomatic treatment of Rheumatism •••••••••••• •••••••• •••••• Symptomatic treatment of Rheumatoid arthritis •••••••••••• •••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Proglumetacin may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Abciximab. Acebutolol Proglumetacin may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Proglumetacin. Acemetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- M01AB14 — Proglumetacin
- Drug Categories
- Acetic Acid Derivatives and Related Substances
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antirheumatic Agents
- Heterocyclic Compounds, Fused-Ring
- Indoles
- Musculo-Skeletal System
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzoylindoles. These are organic compounds containing an indole attached to a benzoyl moiety through the acyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Benzoylindoles
- Direct Parent
- Benzoylindoles
- Alternative Parents
- Glutamic acid and derivatives / Indole-3-acetic acid derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Indolecarboxylic acids and derivatives / 3-alkylindoles / 4-halobenzoic acids and derivatives / Anisoles / Benzoyl derivatives / N-alkylpiperazines show 19 more
- Substituents
- 1,4-diazinane / 3-alkylindole / 4-halobenzoic acid or derivatives / Alkyl aryl ether / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Anisole / Aromatic heteropolycyclic compound show 46 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- aromatic ether, carboxylic ester, benzamides, monochlorobenzenes, N-alkylpiperazine, N-acylindole (CHEBI:76263)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FV919079LU
- CAS number
- 57132-53-3
- InChI Key
- PTXGHCGBYMQQIG-UHFFFAOYSA-N
- InChI
- InChI=1S/C46H58ClN5O8/c1-5-21-51(22-6-2)46(57)40(48-44(55)34-11-8-7-9-12-34)18-20-42(53)59-29-10-23-49-24-26-50(27-25-49)28-30-60-43(54)32-38-33(3)52(41-19-17-37(58-4)31-39(38)41)45(56)35-13-15-36(47)16-14-35/h7-9,11-17,19,31,40H,5-6,10,18,20-30,32H2,1-4H3,(H,48,55)
- IUPAC Name
- 3-{4-[2-({2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl}oxy)ethyl]piperazin-1-yl}propyl 4-(dipropylcarbamoyl)-4-(phenylformamido)butanoate
- SMILES
- CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)CC2=C(C)N(C(=O)C3=CC=C(Cl)C=C3)C3=C2C=C(OC)C=C3)CC1)NC(=O)C1=CC=CC=C1
References
- General References
- AIFA Product Information: Proxil (proglumetacin) oral tablets [Link]
- External Links
- KEGG Drug
- D08427
- ChemSpider
- 4752
- 34769
- ChEBI
- 76263
- ChEMBL
- CHEMBL2105825
- Wikipedia
- Proglumetacin
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Suppository Rectal Tablet, film coated Oral 300 mg Capsule Oral 75 mg Cream Topical 5 % Ointment Topical 5 % Suppository Rectal 200 mg Tablet Oral 150 mg Tablet Oral 300 mg Capsule Oral 150 mg Tablet, coated Oral 300 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00116 mg/mL ALOGPS logP 5.94 ALOGPS logP 5.72 Chemaxon logS -5.9 ALOGPS pKa (Strongest Acidic) 15.04 Chemaxon pKa (Strongest Basic) 7.8 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 139.72 Å2 Chemaxon Rotatable Bond Count 23 Chemaxon Refractivity 232.88 m3·mol-1 Chemaxon Polarizability 94.75 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 284.27383 predictedDeepCCS 1.0 (2019) [M+H]+ 286.16928 predictedDeepCCS 1.0 (2019) [M+Na]+ 292.04642 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:43 / Updated at May 29, 2021 18:11